Share：
Share this content in WeChat
X
[Chinese][PDF]3794
• Clinical Article •
Imaging radiomics features based on DCE-MRI combined with ADC in predicting expression level of Ki-67 in breast cancer
HAN Jianjian  MA Wenjun  MA Peiqi  XIE Yuhai 

HAN J J, MA W J, MA P Q, et al. Imaging radiomics features based on DCE-MRI combined with ADC in predicting expression level of Ki-67 in breast cancer[J]. Chin J Magn Reson Imaging, 2023, 14(8): 63-67, 85. DOI:10.12015/issn.1674-8034.2023.08.010.


[Abstract] Objective To investigate the clinical value of imaging radiomics features based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with apparent diffusion coefficient (ADC) in predicting the expression level of Ki-67 in breast cancer.Materials and Methods MRI images of 234 patients with breast cancer confirmed by pathology from December 2018 to December 2021 were retrospectively analyzed. According to postoperative immunohistochemical results, the tumors were divided into the Ki-67 high expression group (n=180) and low expression group (n=54). 1906 radiomics features were extracted form the first phase of the DCE-MRI by semi-automatic separation method. Using intraclass correlation coefficient (ICC), the linear correlation analysis and the least absolute shrinkage and selection operator (LASSO), four features were selected to construct the radiomics model. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic effectiveness of the radiomics, average ADC values and combined models. Calibration curves and decision curves were used to evaluate the clinical usefulness of the predictive model.Results A total of 1906 features were extracted from the tumor body, 207 features were excluded by ICC analysis, 1626 features were excluded by linear correlation analysis, and the remaining 73 features were selected by LASSO dimensionality reduction to select 4 optimal omics features. Four radiomics features and the average ADC values were significantly different between two groups (P＜0.05). Radiomics model, the average ADC value and the combined model predicted that the area under the curve (AUC) of Ki-67 high expression were 0.820, 0.676 and 0.856, respectively, with statistically significant differences each other (P＜0.05). The combined model had the best predictive efficiency for Ki-67 expression, and its AUC, sensitivity and specificity were 0.856, 88.3% and 74.1%, calibration curves and decision curves showed that the combined model had clinical application value.Conclusions The combined model which constructed by the images radiomics features based on DCE-MRI and the average ADC values has high efficacy in predicting Ki-67 expression in breast cancer.The combined model is superior to the radiomics model and the average ADC value.
[Keywords] breast cancer；Ki-67；radiomics；dynamic contrast-enhanced；diffusion weighted imaging；magnetic resonance imaging

HAN Jianjian1   MA Wenjun2   MA Peiqi3   XIE Yuhai2*  

1 Department of Radiology, the First Affiliated Hospital of Wannan Medical College, Wuhu 241000, China

2 Department of Radiology, Taihe People's Hospital/Taihe Hospital Affiliated to Wannan Medical College, Fuyang 236600, China

3 Department of Radiology, Fuyang People's Hospital, Fuyang 236000, China

Corresponding author: Xie YH, E-mail: xyhdoctor@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Scientific Research Project of Wannan Medical College (No. JXYY202139).
Received  2022-09-16
Accepted  2023-07-21
DOI: 10.12015/issn.1674-8034.2023.08.010
HAN J J, MA W J, MA P Q, et al. Imaging radiomics features based on DCE-MRI combined with ADC in predicting expression level of Ki-67 in breast cancer[J]. Chin J Magn Reson Imaging, 2023, 14(8): 63-67, 85. DOI:10.12015/issn.1674-8034.2023.08.010.

[1]
KATSURA C, OGUNMWONYI I, KANKAM H K, et al. Breast cancer: presentation, investigation and management[J]. Br J Hosp Med, 2022, 83(2): 1-7. DOI: 10.12968/hmed.2021.0459.
[2]
DAVEY M G, HYNES S O, KERIN M J, et al. Ki-67 as a prognostic biomarker in invasive breast cancer[J/OL]. Cancers, 2021, 13(17): 4455 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/34503265/. DOI: 10.3390/cancers13174455.
[3]
PEI B, CHENG L. Correlation between lymph node metastasis ratio and prognosis of breast cancer with different molecular subtypes[J]. Chin J Cancer Biother, 2019, 26(7): 776-781. DOI: 10.3872/j.issn.1007-385x.2019.07.009.
[4]
SONG Q, HU Y T, YANG Y, et al. Correlation between expression of proliferation cell nuclear antigen protein and pathological characteristics in breast cancer[J]. Chin J Exp Surg, 2020, 37(2): 317-320. DOI: 10.3760/cma.j.issn.1001-9030.2020.02.034.
[5]
LIU J N, ZHANG J G, GUO B L, et al. Values of Ki-67 expression level in predicting pathological complete response following neoadjuvant chemotherapy in breast cancer patients[J]. Chin J Gen Surg, 2018, 27(5): 608-614. DOI: 10.3978/j.issn.1005-6947.2018.05.013.
[6]
ZHANG J, HUANG Y B, CHEN J H, et al. Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer[J/OL]. World J Surg Oncol, 2021, 19(1): 284 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/34537053/. DOI: 10.1186/s12957-021-02398-w.
[7]
BONELLI L A, CALABRESE M, BELLI P, et al. MRI versus Mammography plus Ultrasound in Women at Intermediate Breast Cancer Risk: study Design and Protocol of the MRIB Multicenter, Randomized, Controlled Trial[J/OL]. Diagnostics, 2021, 11(9): 1635 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/34573983/. DOI: 10.3390/diagnostics11091635.
[8]
CHOI B B. Dynamic contrast enhanced-MRI and diffusion-weighted image as predictors of lymphovascular invasion in node-negative invasive breast cancer[J/OL]. World J Surg Oncol, 2021, 19(1): 76 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/33722246/. DOI: 10.1186/s12957-021-02189-3.
[9]
BAYSAL B, BAYSAL H, ESER M B, et al. Radiomics features based on MRI-ADC maps of patients with breast cancer: relationship with lesion size, features stability, and model accuracy[J]. Medeni Med J, 2022, 37(3): 277-288. DOI: 10.4274/MMJ.galenos.2022.70094.
[10]
ZHANG Y, ZHU Y F, ZHANG K, et al. Invasive ductal breast cancer: preoperative predict Ki-67 index based on radiomics of ADC maps[J]. Radiol Med, 2020, 125(2): 109-116. DOI: 10.1007/s11547-019-01100-1.
[11]
MING J, CHEN Y, LIU Y, et al. Value of preoperative prediction of Ki-67 expression in breast cancer based on DCE-MRI intratumoral combined with peritumoral radiomics model[J]. Chin J Magn Reson Imag, 2022, 13(10): 132-137, 149. DOI: 10.12015/issn.1674-8034.2022.10.020.
[12]
GOLDHIRSCH A, WINER E P, COATES A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223. DOI: 10.1093/annonc/mdt303.
[13]
MA M M, GAN L Y, JIANG Y, et al. Radiomics analysis based on automatic image segmentation of DCE-MRI for predicting triple-negative and nontriple-negative breast cancer[J/OL]. Comput Math Methods Med, 2021, 2021: 2140465 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/34422088/. DOI: 10.1155/2021/2140465.
[14]
ZHANG C M, DING Z M, CHEN P, et al. Prediction of HER-2 expression in breast cancer patients based on DCE-MRI intratumor and peritumoral imaging combined with TIC typing and Ki-67[J]. Chin J Magn Reson Imag, 2023, 14(4): 68-75. DOI: 10.12015/issn.1674-8034.2023.04.012.
[15]
ZHANG S H, WANG X L, YANG Z, et al. Intra- and peritumoral radiomics model based on early DCE-MRI for preoperative prediction of molecular subtypes in invasive ductal breast carcinoma: a multitask machine learning study[J]. Front Oncol, 2022, 12: 905551 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/35814460/. DOI: 10.3389/fonc.2022.905551.
[16]
ZHU Y Q, JI H, ZHU Y F, et al. Predictive value of preoperative MRI-based nomogram for axillary lymph node metastasis in breast cancer[J]. Chin J Magn Reson Imag, 2022, 13(5: 52-58. DOI: 10.12015/issn.1674-8034.2022.05.010.
[17]
JIANG Y, MA M M, CHENG Y J, et al. Feasibility study of predicting axillary lymph node metastasis of breast cancer using radiomics analysis based on dynamic contrast-enhanced MRI[J]. Chin J Radiol, 2022, 56(6: 631-635. DOI: 10.3760/cma.j.cn112149-20210810-00460.
[18]
ZHU Y D, YANG L, SHEN H L. Value of the application of CE-MRI radiomics and machine learning in preoperative prediction of sentinel lymph node metastasis in breast cancer[J/OL]. Front Oncol, 2021, 11: 757111 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/34868967/. DOI: 10.3389/fonc.2021.757111.
[19]
YU Y F, HE Z F, OUYANG J, et al. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: a machine learning, multicenter study[J/OL]. EBioMedicine, 2021, 69: 103460 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/34233259/. DOI: 10.1016/j.ebiom.2021.103460.
[20]
SONG D L, CUI S J, YANG F, et al. Radiomics model based on dynamic contrast-enhanced MRI for predicting breast cancer non-pathological complete response after neoadjuvant chemotherapy[J]. Chin J Med Imag Technol, 2021, 37(4: 547-551. DOI: 10.13929/j.issn.1003-3289.2021.04.016.
[21]
YAO C, YANG Z Q, YANG J D, et al. A nomogram based on DCE-MRI Radscore and hormone receptor status for predicting drug insensitive to neoadjuvant chemotherapy in breast cancer patients[J]. Int J Med Radiol, 2022, 45(2: 130-134. DOI: 10.19300/j.2022.L19006.
[22]
ZHANG J M, DONG J N, WU Y Y, et al. The differential diagnostic performance of spectral CT quantitative parameters combined with texture analysis on benign and malignant thyroid nodules[J]. J Pract Radiol, 2022, 38(7: 1069-1073. DOI: 10.3969/j.issn.1002-1671.2022.07.006.
[23]
KIM D, JENSEN L J, ELGETI T, et al. Radiomics for everyone: a new tool simplifies creating parametric maps for the visualization and quantification of radiomics features[J]. Tomography, 2021, 7(3: 477-487. DOI: 10.3390/tomography7030041.
[24]
WANG Y B, PU H. Morphological features of breast cancer enhanced MRI, ADC values and their relationships with related molecular biomarkers[J]. J Pract Radiol, 2020, 36(2: 219-222. DOI: 10.3969/j.issn.1002-1671.2020.02.012.
[25]
YAN F S, ZHOU J, BAI Y, et al. Clinical and DCE-MRI features of breast cancer in patients with different Ki-67 status[J]. Chin J Med Imag Technol, 2019, 35(11: 1657-1662. DOI: 10.13929/j.1003-3289.201902066.
[26]
WANG M, LIU Z, WEN J, et al. The value of radiomics features derived from the T2WI-FS assisted preoperative prediction of axillary lymph node metastasis of breast cancer[J]. Oncoradiology, 2022, 31(1: 28-35. DOI: 10.19732/j.cnki.2096-6210.2022.01.006.
[27]
CHOI B B. Effectiveness of ADC difference value on pre-neoadjuvant chemotherapy MRI for response evaluation of breast cancer[J/OL]. Technol Cancer Res Treat, 2021, 20: 15330338211039129 [2022-09-15]. https://pubmed.ncbi.nlm.nih.gov/34519583/. DOI: 10.1177/15330338211039129.
[28]
HOTTAT N A, BADR D A, LECOMTE S, et al. Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements[J]. Eur Radiol, 2022, 32(6: 4067-4078. DOI: 10.1007/s00330-021-08462-z.
[29]
HONG J, WANG D Q, YIN R G, et al. The correlation between diffusion-weighted magnetic resonance imaging and Ki-67 in invasive ductal carcinoma of breast[J]. J Jiangsu Univ Med Ed, 2019, 29(5: 441-443, 455. DOI: 10.13312/j.issn.1671-7783.y190096.
[30]
REN C C, ZOU Y, ZHANG X D, et al. Diagnostic value of diffusion-weighted imaging-derived apparent diffusion coefficient and its association with histological prognostic factors in breast cancer[J]. Oncol Lett, 2019, 18(3: 3295-3303. DOI: 10.3892/ol.2019.10651.
[31]
REN A X, WEI M C, YANG Y Q, et al. Detection and value of serum antigen KI-67 (ki67) in clinical diagnosis of breast cancer patients[J]. Chin J Cell Mol Immunol, 2020, 36(12: 1124-1128. DOI: 10.13423/j.cnki.cjcmi.009119.

PREV Value of whole volume histogram features from Synthetic MRI in differentiating benign and malignant breast tumor
NEXT MRI enhanced features, pathology and prognosis of intrahepatic mass-forming cholangiocarcinoma
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn